title: [Age-related macular degeneration].
authors.affiliation: Augenklinik der Ludwig-Maximilians-Universität, München. Marcus.Kernt@med.uni-muenchen.de
authors.forename: Marcus
authors.initials: M
authors.lastname: Kernt
authors.forename: Armin
authors.initials: A
authors.lastname: Wolf
authors.forename: Anselm
authors.initials: A
authors.lastname: Kampik
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D000068258:Bevacizumab; D001766:Blindness / Q000209:etiology; D003430:Cross-Sectional Studies; D057092:Geographic Atrophy / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D056687:Off-Label Use; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D015354:Vision, Low / Q000209:etiology; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000975:Antioxidants; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab